TY - JOUR
T1 - The ISTH bleeding assessment tool as predictor of bleeding events in inherited platelet disorders
T2 - Communication from the ISTH SSC Subcommittee on Platelet Physiology
AU - Gresele, Paolo
AU - Falcinelli, Emanuela
AU - Bury, Loredana
AU - Pecci, Alessandro
AU - Alessi, Marie Christine
AU - Borhany, Munira
AU - Heller, Paula G.
AU - Santoro, Cristina
AU - Cid, Ana Rosa
AU - Orsini, Sara
AU - Fontana, Pierre
AU - De Candia, Erica
AU - Podda, Gianmarco
AU - Kannan, Meganathan
AU - Jurk, Kerstin
AU - Castaman, Giancarlo
AU - Falaise, Céline
AU - Guglielmini, Giuseppe
AU - Noris, Patrizia
AU - Zaninetti, Carlo
AU - Fiore, Mathieu
AU - Tosetto, Alberto
AU - Zuniga, Pamela
AU - Miyazaki, Koji
AU - Dupuis, Arnaud
AU - Hayward, Catherine
AU - Casonato, Alessandra
AU - Grandone, Elvira
AU - Mazzucconi, Maria Gabriella
AU - James, Paula
AU - Fabris, Fabrizio
AU - Henskens, Yvonne
AU - Napolitano, Mariasanta
AU - Curnow, Jennifer
AU - Gkalea, Vasiliki
AU - Fedor, Marian
AU - Lambert, Michele P.
AU - Zieger, Barbara
AU - Barcella, Luca
AU - Cosmi, Benilde
AU - Giordano, Paola
AU - Porri, Claudia
AU - Melazzini, Federica
AU - Abid, Madiha
AU - Glembotsky, Ana C.
AU - Ferrara, Grazia
AU - Russo, Alexandra
AU - Deckmyn, Hans
AU - Frelinger, Andrew L.
AU - Harrison, Paul
AU - BAT-VAL Study Investigators
N1 - Funding Information:
LB and EF were supported by a scholarship grant from Fondazione Umberto Veronesi. The authors thank Dr. Francesco Rodeghiero (Department of Cell Therapy and Hematology San Bortolo Hospital and Hematology, Project Foundation, Vicenza, Italy) for his critical review of the manuscript. The contribution of Bernhard Lammle (Center for Thrombosis and Hemostasis, University Medical Center, Mainz, Germany), Alice Trinchero (Center for Thrombosis and Hemostasis, University Medical Center, Mainz, Germany), Silvia Ferrari and Davide Rancitelli (University of Padua, Italy), Abinaya Arulselvan (Children’s Hospital of Philadelphia, Philadelphia, USA), Giuseppe Lassandro (University of Bari, Italy), and Analia Sanchez Luceros (Hospital Italiano, Rosario, Argentina) for patient enrollment is kindly acknowledged.
Funding Information:
LB and EF were supported by a scholarship grant from Fondazione Umberto Veronesi. The authors thank Dr. Francesco Rodeghiero (Department of Cell Therapy and Hematology San Bortolo Hospital and Hematology, Project Foundation, Vicenza, Italy) for his critical review of the manuscript. The contribution of Bernhard Lammle (Center for Thrombosis and Hemostasis, University Medical Center, Mainz, Germany), Alice Trinchero (Center for Thrombosis and Hemostasis, University Medical Center, Mainz, Germany), Silvia Ferrari and Davide Rancitelli (University of Padua, Italy), Abinaya Arulselvan (Children?s Hospital of Philadelphia, Philadelphia, USA), Giuseppe Lassandro (University of Bari, Italy), and Analia Sanchez Luceros (Hospital Italiano, Rosario, Argentina) for patient enrollment is kindly acknowledged.
Publisher Copyright:
© 2021 International Society on Thrombosis and Haemostasis
PY - 2021/5/1
Y1 - 2021/5/1
N2 - Background: The ISTH Bleeding Assessment Tool (ISTH-BAT) has been validated for clinical screening of suspected von Willebrand disease (VWD) and for bleeding prediction. Recently it has been validated for subjects with inherited platelet disorders (IPD) (BAT-VAL study). Objectives: To determine whether the ISTH-BAT bleeding score (BS) predicts subsequent bleeding events requiring treatment in IPD patients. Methods: Patients with IPD, type 1 VWD (VWD-1) and age- and sex-matched healthy controls enrolled in the BAT-VAL study were prospectively followed-up for 2 years and bleeding episodes requiring treatment were recorded. Results: Of the 1098 subjects initially enrolled, 955 were followed-up and 124 suffered hemorrhages during follow-up, 60% of whom had inherited platelet function disorders (IPFD). Total number of events was significantly higher in IPFD (n = 235) than VWD-1 (n = 52) or inherited thrombocytopenia (IT; n = 20). Events requiring transfusions were 66% in IPFD, 5.7% in VWD-1, and 3% in IT. Baseline BS was significantly higher in IPFD patients with a bleeding event at follow-up than in those without (p <.01) and the percentage of subjects suffering a bleeding event increased proportionally to baseline BS quartile. A significant association between the BS and the chance of suffering severe bleeding was found in the overall, IPFD, and VWD-1 populations. Similar results were obtained for the pediatric population. Conclusions: Inherited platelet function disorder patients with high BS at enrollment are more likely to suffer from bleeding events requiring treatment at follow-up. Moreover, the higher the baseline BS quartile the greater the incidence of subsequent events, suggesting that independently from diagnosis a high BS is associated with a greater risk of subsequent hemorrhage.
AB - Background: The ISTH Bleeding Assessment Tool (ISTH-BAT) has been validated for clinical screening of suspected von Willebrand disease (VWD) and for bleeding prediction. Recently it has been validated for subjects with inherited platelet disorders (IPD) (BAT-VAL study). Objectives: To determine whether the ISTH-BAT bleeding score (BS) predicts subsequent bleeding events requiring treatment in IPD patients. Methods: Patients with IPD, type 1 VWD (VWD-1) and age- and sex-matched healthy controls enrolled in the BAT-VAL study were prospectively followed-up for 2 years and bleeding episodes requiring treatment were recorded. Results: Of the 1098 subjects initially enrolled, 955 were followed-up and 124 suffered hemorrhages during follow-up, 60% of whom had inherited platelet function disorders (IPFD). Total number of events was significantly higher in IPFD (n = 235) than VWD-1 (n = 52) or inherited thrombocytopenia (IT; n = 20). Events requiring transfusions were 66% in IPFD, 5.7% in VWD-1, and 3% in IT. Baseline BS was significantly higher in IPFD patients with a bleeding event at follow-up than in those without (p <.01) and the percentage of subjects suffering a bleeding event increased proportionally to baseline BS quartile. A significant association between the BS and the chance of suffering severe bleeding was found in the overall, IPFD, and VWD-1 populations. Similar results were obtained for the pediatric population. Conclusions: Inherited platelet function disorder patients with high BS at enrollment are more likely to suffer from bleeding events requiring treatment at follow-up. Moreover, the higher the baseline BS quartile the greater the incidence of subsequent events, suggesting that independently from diagnosis a high BS is associated with a greater risk of subsequent hemorrhage.
KW - bleeding prediction
KW - bleeding score
KW - inherited platelet disorders
KW - mild-moderate bleeding disorders
KW - von Willebrand disease
U2 - 10.1111/jth.15263
DO - 10.1111/jth.15263
M3 - Article
SN - 1538-7933
VL - 19
SP - 1364
EP - 1371
JO - Journal of Thrombosis and Haemostasis
JF - Journal of Thrombosis and Haemostasis
IS - 5
ER -